List of Excipients in Branded Drug DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION

« Back to Dashboard

Generic Drugs Containing DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION

Company	Ingredient	NDC	Excipient
Micro Labs Limited	dorzolamide hydrochloride and timolol maleate	42571-147	BENZALKONIUM CHLORIDE
Micro Labs Limited	dorzolamide hydrochloride and timolol maleate	42571-147	HYDROXYETHYL CELLULOSE
Micro Labs Limited	dorzolamide hydrochloride and timolol maleate	42571-147	MANNITOL
Micro Labs Limited	dorzolamide hydrochloride and timolol maleate	42571-147	SODIUM HYDROXIDE
Micro Labs Limited	dorzolamide hydrochloride and timolol maleate	42571-147	TRISODIUM CITRATE DIHYDRATE
Micro Labs Limited	dorzolamide hydrochloride and timolol maleate	42571-147	WATER

What are the Most Frequently-Used Excipients in DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION?

# Of NDCs	Excipient
4	BENZALKONIUM CHLORIDE
4	HYDROXYETHYL CELLULOSE
4	MANNITOL
4	SODIUM HYDROXIDE
4	TRISODIUM CITRATE DIHYDRATE
4	WATER

Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution: Excipient Strategy and Commercial Opportunities

Last updated: September 25, 2026

Dorzolamide hydrochloride/timolol maleate ophthalmic solution is a mature fixed-dose glaucoma combination with established generic competition. The commercial opportunity is not based on new-molecule exclusivity. It is based on preservative-free delivery, multidose container technology, tolerability, manufacturing efficiency, differentiated packaging, and access to markets where Cosopt-equivalent products remain underpenetrated.

The reference product, Cosopt, combines dorzolamide hydrochloride 2% and timolol maleate 0.5% in an aqueous ophthalmic solution. The product lowers intraocular pressure through two complementary mechanisms: carbonic anhydrase inhibition by dorzolamide and beta-adrenergic blockade by timolol. FDA-approved preservative-free Cosopt PF creates the main formulation benchmark for premium product development.[1]

What is the formulation of dorzolamide hydrochloride and timolol maleate ophthalmic solution?

The standard formulation contains dorzolamide hydrochloride equivalent to dorzolamide 20 mg/mL and timolol maleate equivalent to timolol 5 mg/mL.

Component	Function in the formulation
Dorzolamide hydrochloride	Carbonic anhydrase inhibitor active ingredient
Timolol maleate	Beta-blocker active ingredient
Hydroxyethyl cellulose	Viscosity modifier and retention aid
Mannitol	Tonicity adjustment and stabilizer
Sodium citrate dihydrate	Buffering and pH control
Sodium hydroxide	pH adjustment
Benzalkonium chloride, in preserved products	Antimicrobial preservative
Purified water	Vehicle

The reference preserved formulation uses benzalkonium chloride, commonly abbreviated BAK, at approximately 0.0075%. Cosopt PF removes BAK and uses single-use containers, reducing preservative exposure to the ocular surface.[1]

The formulation must maintain chemical stability for two active ingredients with different physicochemical characteristics. Dorzolamide is supplied as a hydrochloride salt and is relatively soluble in aqueous systems. Timolol is supplied as a maleate salt. The formulation therefore depends on controlled pH, ionic strength, buffer capacity, and container compatibility.

Which excipients are most important for product differentiation?

Excipient selection determines whether a product competes as a low-cost generic, a preservative-free product, or a premium ocular-surface formulation.

Benzalkonium chloride strategy

BAK is effective against microbial contamination and supports multidose packaging. Its disadvantages are ocular-surface toxicity and potential worsening of dry-eye symptoms with chronic exposure. Repeated BAK exposure has been associated with epithelial disruption, inflammation, tear-film instability, and reduced tolerability in patients receiving long-term glaucoma therapy.[2]

A BAK-preserved product has the lowest development and packaging cost. It is suitable for price-sensitive tenders and conventional pharmacy distribution.

A preservative-free product has greater commercial differentiation but requires a validated sterile container system. The principal options are:

• Single-dose blow-fill-seal ampoules.
• Multidose preservative-free valve containers.
• Multidose containers with antimicrobial or microbial-retentive technology.
• Unit-dose strips supplied in cartons for chronic home use.

A preservative-free product cannot simply remove BAK from the reference formula. The sponsor must establish container closure integrity, microbial ingress protection, extractables and leachables, dose uniformity, usability, and in-use stability.

Hydroxyethyl cellulose strategy

Hydroxyethyl cellulose increases viscosity and can improve ocular residence time. It also affects:

• Drop size.
• Shake or inversion behavior.
• Patient-perceived comfort.
• Delivery through the container orifice.
• Filtration and sterile processing.
• Interactions with the preservative system.

Increasing viscosity may support a reduced-frequency or comfort-positioning claim only if supported by clinical and pharmacokinetic evidence. It can also produce larger drops or a slower discharge profile, which may increase drug wastage if the container is not optimized.

Alternative viscosity agents, including hypromellose or low-substituted cellulose derivatives, may create formulation freedom but can introduce new risks involving clarity, filterability, viscosity drift, and nozzle plugging. A sponsor should avoid changing the viscosity system without a clear product-performance objective.

Buffer and pH strategy

Sodium citrate and sodium hydroxide provide pH control. The reference product is formulated in an acidic-to-near-neutral range, with the Cosopt label identifying a pH of approximately 5.5 to 5.9.[1]

The pH window must balance:

• Solubility of both active ingredients.
• Chemical degradation.
• Ocular comfort.
• Preservative efficacy.
• Container compatibility.
• Tonicity and precipitation risk.

A narrower pH specification can improve batch consistency but may increase manufacturing rejection risk. A broader specification can reduce manufacturing cost but may weaken stability and comfort margins.

Mannitol and tonicity control

Mannitol contributes to osmolality and may improve solution stability. Ophthalmic products should be close enough to physiological tonicity to limit stinging and reflex tearing, while avoiding an osmolality range that increases precipitation or chemical instability.

The osmolality target should be established as a finished-product critical quality attribute rather than inferred solely from excipient concentration. Changes in buffer salts, preservative concentration, or active-ingredient counterions can shift osmolality materially.

What formulation patents protect dorzolamide and timolol ophthalmic products?

The original Cosopt intellectual-property position was associated with Merck’s combination product and its formulation and method-of-use rights. Those rights do not create a meaningful current barrier comparable to a newly launched branded ophthalmic product because dorzolamide/timolol fixed-dose solutions have been genericized for many years.

Current product value is more likely to depend on secondary rights involving:

• Preservative-free multidose containers.
• Valve and nozzle architecture.
• Unit-dose packaging.
• Low-drop-volume delivery.
• Compatibility between the formulation and container.
• Specific viscosity or pH ranges.
• Improved stability under storage or in-use conditions.
• Manufacturing processes that reduce particulate burden.
• Pediatric or selected glaucoma-treatment methods.

The strongest defensible position generally comes from a combination of formulation and device claims. A composition claim covering only common excipients such as mannitol, sodium citrate, hydroxyethyl cellulose, and water is vulnerable if the same excipient architecture appears in the reference label or prior art.

A sponsor seeking patent value should focus on measurable product attributes. Examples include a defined preservative-free multidose system that passes microbial challenge testing, a narrow drop-volume range, improved stability in a specified container, or a demonstrated reduction in ocular-surface toxicity.

When does dorzolamide/timolol lose exclusivity?

The product has already lost primary small-molecule exclusivity in the United States. FDA approved Cosopt under NDA 020753, and generic dorzolamide hydrochloride/timolol maleate ophthalmic solutions are available through the ANDA pathway.[1][3]

Exclusivity category	Current commercial position
New chemical entity exclusivity	Expired
Fixed-combination exclusivity	Expired
Core formulation exclusivity	Expired or commercially superseded
Orange Book patent barrier	No core barrier generally relied upon by the market
Biosimilar exclusivity	Not applicable
Regulatory opportunity	ANDA for equivalent product; 505(b)(2) may support differentiated delivery or formulation

The relevant business question is therefore not when the molecule loses exclusivity. It is whether a new product can obtain a premium or defend a market niche after generic entry.

What is the FDA regulatory status and Orange Book position?

Dorzolamide/timolol ophthalmic solution is an FDA-approved prescription ophthalmic drug. Conventional generic versions generally use the ANDA route and must demonstrate pharmaceutical equivalence and bioequivalence or applicable therapeutic equivalence requirements.

For a conventional solution, the sponsor must address:

• Same active ingredients and strengths.
• Same dosage form and route.
• Equivalent quality attributes.
• Sterility.
• Particulate matter.
• pH and osmolality.
• Preservative content, where applicable.
• Container-closure integrity.
• Stability.
• Drop size and delivery performance.

A preservative-free multidose product, a substantially different container, or a formulation with a new clinical performance proposition may require a 505(b)(2) strategy rather than a straightforward ANDA. The pathway depends on the extent of formulation, device, and labeling differences.

Orange Book value is limited for the mature reference product. The more commercially relevant intellectual property may sit in separate device, packaging, or formulation patents that do not necessarily create a broad barrier to standard generic solutions.[3]

How strong is the patent estate for dorzolamide/timolol products?

The core patent estate is weak as a barrier to ordinary generic entry but can be stronger for differentiated delivery systems.

Patent target	Relative strength	Commercial rationale
Basic aqueous combination solution	Low	Mature composition and extensive prior art
BAK-preserved formulation using conventional excipients	Low	Close to known reference formulation
Preservative-free unit-dose product	Moderate	Packaging and stability claims may be defensible
Preservative-free multidose device	Moderate to high	Device and microbial-protection claims can create differentiation
Low-volume or controlled-drop delivery	Moderate	Performance claims can support premium positioning
New ocular-surface tolerability profile	Moderate	Requires clinical substantiation
Manufacturing process with lower impurities	Moderate	May protect scale-up or quality advantage
Broad method-of-use claims	Low to moderate	Vulnerable to prior treatment methods and obviousness challenges

A strong portfolio should include composition, container, manufacturing, and use claims with overlapping but independent scope. Reliance on one narrow formulation patent creates a material design-around risk.

What generic entry risks exist?

Generic entry risk remains high for the standard BAK-preserved solution. The product is well understood, the dosage form is an aqueous solution, and the clinical demand is established.

The main barriers are technical rather than pharmacological:

• Maintaining clarity throughout shelf life.
• Preventing precipitation or crystallization.
• Controlling active-ingredient degradation.
• Achieving sterile filtration without active loss.
• Demonstrating preservative effectiveness.
• Avoiding nozzle blockage.
• Controlling drop size across temperature and orientation.
• Ensuring compatibility with plastic containers.
• Meeting ophthalmic particulate specifications.

Generic entrants may compete aggressively on price, especially in government and managed-care channels. A standard preserved product has limited ability to command a premium unless it has supply reliability, a preferred container, or market access advantages.

What commercial opportunities exist for excipient and delivery innovation?

Preservative-free chronic-use products

The most credible premium opportunity is a preservative-free version for patients with ocular-surface disease, chronic topical therapy, contact-lens-related intolerance, or high cumulative exposure to BAK-containing drops.

The product should be positioned around tolerability and treatment persistence, not merely the absence of BAK. Evidence should include ocular-surface assessments, patient-reported comfort, tear-film measures, and discontinuation rates.

Preservative-reduced formulations

A reduced-BAK product may lower formulation and packaging costs compared with a fully preservative-free system. Its commercial value is less clear because it may not provide the same clinical differentiation and may still face ocular-surface objections.

Unit-dose packaging

Unit-dose products can command a price premium and simplify preservative-free delivery. Their disadvantages are higher packaging cost, greater material use, storage burden, and potential patient confusion. The strongest markets are likely to be chronic users with documented preservative intolerance and institutional channels that value standardized sterile dosing.

Multidose preservative-free systems

Multidose systems improve convenience and reduce packaging waste compared with ampoules. They require greater device investment but can support a stronger commercial proposition:

• No daily opening of ampoules.
• Lower waste.
• Easier travel and home use.
• Better differentiation from ordinary generics.
• Potential device patent protection.

Drop-volume reduction

Conventional ophthalmic drops often exceed the conjunctival sac capacity. A controlled-volume system may reduce overflow, systemic absorption, and product wastage. A smaller delivered dose must still provide consistent ocular exposure and meet dose-uniformity requirements.

This strategy could be particularly relevant for timolol because systemic beta-blocker exposure creates clinically important concerns in susceptible patients. Product claims must remain within the approved label unless supported through the applicable regulatory pathway.

Combination adherence

The fixed combination replaces two separate bottles and may reduce dosing complexity. A commercial program can focus on adherence, refill persistence, and total treatment burden. A sponsor should avoid unsupported claims that the combination improves outcomes beyond the approved indication.

How does dorzolamide/timolol compare with competing glaucoma products?

Product category	Main advantage	Main limitation	Excipient opportunity
Dorzolamide/timolol solution	Two mechanisms in one bottle	Stinging, preservative exposure, twice-daily use	Preservative-free delivery and comfort
Timolol monotherapy	Low cost and familiarity	Single mechanism; systemic beta-blocker risk	Low-volume and preservative-free formats
Prostaglandin analogs	Strong pressure reduction and once-daily dosing	Ocular-surface and cosmetic effects	Improved tolerability and packaging
Brimonidine/timolol	Combination therapy	Allergy and systemic tolerability concerns	Preservative-free systems
Netarsudil/latanoprost	Potent combination option	Higher cost and hyperemia	Stability and premium delivery
Separate dorzolamide plus timolol	Flexible dosing	More bottles and lower adherence	Fixed-dose convenience

Dorzolamide/timolol is most competitive where affordability, established efficacy, and combination convenience matter. It is less competitive when once-daily administration or preservative avoidance drives prescribing decisions.

Which companies are challenging the reference product?

Generic manufacturers and ophthalmic specialists have commercialized dorzolamide hydrochloride/timolol maleate ophthalmic solutions in the United States and other regulated markets. Competition is fragmented across generic companies, contract manufacturers, and regional ophthalmic suppliers.

The market is more likely to experience price competition than patent litigation over the basic solution. A differentiated preservative-free product would shift the competitive field toward device reliability, supply continuity, reimbursement, and physician adoption.

A new entrant should assess:

• FDA-approved ANDA holders.
• Therapeutically equivalent products in the Orange Book.
• Current wholesale acquisition cost.
• Medicaid and Medicare reimbursement.
• Hospital and group-purchasing contracts.
• Supplier reliability and shortage history.
• Regional registration requirements.
• Local manufacturing or packaging economics.

What licensing and partnership opportunities exist?

The most attractive licensing targets are not the active ingredients. They are:

1. Preservative-free multidose container technology.
2. Ophthalmic blow-fill-seal manufacturing capacity.
3. Low-volume dropper systems.
4. Sterile filtration and aseptic filling platforms.
5. Ocular-surface tolerability data.
6. Regional regulatory registrations.
7. Contract manufacturing relationships in emerging markets.

A formulation owner may license the product to an ophthalmic company with an established sales force, while retaining rights to the device or manufacturing platform. A contract manufacturer can create value by offering a ready-to-file formulation package supported by stability, extractables, and container-closure data.

What geographic markets offer the best opportunity?

The United States is attractive for differentiated preservative-free products but difficult for basic generic entry because of established competition and payer pressure.

Higher-growth opportunities may exist in:

• Latin America, where branded generics remain important.
• Southeast Asia, where glaucoma diagnosis and treatment access are expanding.
• Middle East markets with centralized procurement.
• Selected European markets where preservative-free prescribing is favored.
• Countries with limited availability of fixed-combination glaucoma products.

The regulatory strategy varies. A product may qualify as a generic in one jurisdiction and require a hybrid or abridged application in another, particularly when the container system differs from the reference product.

Key Takeaways

• Dorzolamide hydrochloride/timolol ophthalmic solution is a mature genericized combination.
• The standard BAK-preserved formulation has limited patent and pricing power.
• Preservative-free delivery is the clearest commercial opportunity.
• Multidose preservative-free containers offer stronger differentiation than a simple excipient substitution.
• Hydroxyethyl cellulose, citrate buffer, mannitol, pH, osmolality, and container compatibility are central formulation variables.
• New value is more likely to come from device, packaging, stability, and tolerability claims than from the active ingredients.
• The core product is regulated through established generic pathways, while materially differentiated systems may support a 505(b)(2) strategy.
• Biosimilar risk does not apply because the product contains small-molecule active ingredients.
• Generic entry risk is high for ordinary solutions and lower for technically complex preservative-free systems.
• The strongest portfolio combines formulation patents with container, manufacturing, and delivery-performance claims.

FAQs

Can benzalkonium chloride be removed from dorzolamide/timolol solution without changing the active ingredients?

Yes. A preservative-free formulation can use the same active ingredients, but the container must provide microbial protection through single-dose packaging or validated multidose technology.

Is hydroxyethyl cellulose essential to the formulation?

No. It is a useful viscosity modifier, but alternatives are possible. Any substitution must be evaluated for stability, comfort, drop size, filterability, and container performance.

Does a preservative-free product automatically qualify for a premium price?

No. The premium depends on clinical differentiation, reimbursement, packaging convenience, supply reliability, and evidence that patients value improved tolerability.

Can a generic company patent a new dorzolamide/timolol container?

Yes. Patent protection may be available for a novel container, valve, nozzle, microbial-barrier system, or controlled-drop mechanism if the claims satisfy novelty, non-obviousness, and enablement requirements.

Is a new dorzolamide/timolol ophthalmic solution likely to face biosimilar competition?

No. Biosimilar regulation applies to biological products. Dorzolamide and timolol are small-molecule drugs, so competition proceeds through generic, hybrid, or other small-molecule regulatory pathways.

References

1. U.S. Food and Drug Administration. (2023). Cosopt and Cosopt PF prescribing information. Merck & Co., Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. Baudouin, C., Labbé, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/